Want to see MBX full AI Analyst Report?
Total Valuation
MBX Biosciences, Inc. has a market cap or net worth of $3.30B. The enterprise value is $2.22K.
Market Cap$3.30B
Enterprise Value$2.22K
Share Statistics
MBX Biosciences, Inc. has 48,160,095 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding48,160,095
Owned by Insiders25.68%
Owned by Institutions10.15%
Financial Efficiency
MBX Biosciences, Inc.’s return on equity (ROE) is -0.24 and return on invested capital (ROIC) is -26.51%.
Return on Equity (ROE)-0.24
Return on Assets (ROA)-0.23
Return on Invested Capital (ROIC)-26.51%
Return on Capital Employed (ROCE)-0.27
Revenue Per Employee0.00
Profits Per Employee-1.38M
Employee Count63
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of MBX Biosciences, Inc. is ―. MBX Biosciences, Inc.’s PEG ratio is -0.46.
PE Ratio―
PS Ratio0.00
PB Ratio3.12
Price to Fair Value3.12
Price to FCF-14.06
Price to Operating Cash Flow-39.56
PEG Ratio-0.46
Income Statement
In the last 12 months, MBX Biosciences, Inc. had revenue of 0.00 and earned -86.97M in profits. Earnings per share was -2.38.
Revenue0.00
Gross Profit-248.00K
Operating Income-98.06M
Pretax Income-86.97M
Net Income-86.97M
EBITDA-86.72M
Earnings Per Share (EPS)-2.38
Cash Flow
In the last 12 months, operating cash flow was -82.67M and capital expenditures -2.53M, giving a free cash flow of -85.20M billion.
Operating Cash Flow-82.67M
Free Cash Flow-85.20M
Free Cash Flow per Share-1.77
Dividends & Yields
MBX Biosciences, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.97
52-Week Price Change370.62%
50-Day Moving Average55.05
200-Day Moving Average37.57
Relative Strength Index (RSI)62.57
Average Volume (3m)963.99K
Important Dates
MBX Biosciences, Inc. upcoming earnings date is Nov 5, 2026, Before Open (Confirmed).
Last Earnings DateAug 6, 2026
Next Earnings DateNov 5, 2026
Ex-Dividend Date―
Financial Position
MBX Biosciences, Inc. as a current ratio of 24.62, with Debt / Equity ratio of 0.82%
Current Ratio24.62
Quick Ratio24.62
Debt to Market Cap<0.01
Net Debt to EBITDA0.86
Interest Coverage Ratio0.00
Taxes
In the past 12 months, MBX Biosciences, Inc. has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
MBX Biosciences, Inc. EV to EBITDA ratio is -12.42, with an EV/FCF ratio of -13.15.
EV to Sales0.00
EV to EBITDA-12.42
EV to Free Cash Flow-13.15
EV to Operating Cash Flow-13.47
Balance Sheet
MBX Biosciences, Inc. has $418.58M in cash and marketable securities with $3.34M in debt, giving a net cash position of $415.24M billion.
Cash & Marketable Securities$418.58M
Total Debt$3.34M
Net Cash$415.24M
Net Cash Per Share$8.62
Tangible Book Value Per Share$10.11
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for MBX Biosciences, Inc. is $89.50, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$89.50
Price Target Upside44.35% Upside
Analyst ConsensusStrong Buy
Analyst Count8
Revenue Growth Forecast―
EPS Growth Forecast-4.40%